Dehydration, confusion, and increased thirst are also common side effects
Results indicate that liraglutides potential to reduce CVD risk via improvement of postprandial lipemia
The study found that 83% of those in the Cassia alata group had bowel movements within 24 h, compared to 86% in the Mist
Recently, a number of studies reported the results of CVD trials investigating the effect of GLP-1RAs including lixisenatide, liraglutide, semaglutide, exenatide, albiglutide, dulaglutide, and oral semaglutide in patients with T2DM, and established CVD risk factors [29,30]
Weakened Immune System: The immune-boosting properties of glutathione may also diminish, potentially making the body more susceptible to infections and illnesses
But here's another important caveat: This study only looked at short-term effects